Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D).

Timeline

Start

2018-09-28

Primary completion

2023-03-31

Completion

2023-05-31

Drugs

Indications